Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Gary Ingenito Sells 44,000 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 44,000 shares of the firm’s stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,627,468.99. This represents a 38.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Gary Ingenito also recently made the following trade(s):

• On Tuesday, May 13th, Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00.
• On Wednesday, March 5th, Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $22.09, for a total value of $991,929.36.

Catalyst Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ:CPRX opened at $24.37 on Friday. The firm has a market cap of $2.97 billion, a P/E ratio of 20.65, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16. The business has a fifty day simple moving average of $23.23 and a 200 day simple moving average of $22.47.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Algert Global LLC raised its position in Catalyst Pharmaceuticals by 1.0% during the 1st quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company’s stock worth $1,173,000 after purchasing an additional 470 shares during the last quarter. Hancock Whitney Corp raised its position in Catalyst Pharmaceuticals by 1.4% during the 1st quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company’s stock worth $942,000 after purchasing an additional 525 shares during the last quarter. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 579 shares during the last quarter. Summit Investment Advisors Inc. raised its position in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 580 shares in the last quarter. Finally, Hohimer Wealth Management LLC raised its position in shares of Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company’s stock worth $438,000 after acquiring an additional 629 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on CPRX. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.